Microsatellite instability-high colon cancer was the main tumor model in the initial clinical trials demonstrating anti-PD-1 efficacy [63], and MSI-h is the biomarker behind pembrolizumab’s historical site-agnostic approval [64]. The gene discussed is PDCD1; the disease is neoplasm.